Overview

Properties

Applications

Our Abpromise guarantee covers the use of ab58369 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB
  • Application notesWB: Use at a concentration of 1-5 µg/ml.

    This antibody has only been tested in WB against the recombinant fragment used as immunogen. We have no data on the detection of endogenous protein.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionE3 ubiquitin ligase that, together with UBE2N and UBE2V1, mediates the synthesis of 'Lys-63'-linked-polyubiquitin chains conjugated to proteins, such as IKBKG, AKT1 and AKT2. Also mediates ubiquitination of free/unanchored polyubiquitin chain that leads to MAP3K7 activation. Leads to the activation of NF-kappa-B and JUN. May be essential for the formation of functional osteoclasts. Seems to also play a role in dendritic cells (DCs) maturation and/or activation. Represses c-Myb-mediated transactivation, in B lymphocytes. Adapter protein that seems to play a role in signal transduction initiated via TNF receptor, IL-1 receptor and IL-17 receptor.
    • Tissue specificityExpressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas.
    • PathwayProtein modification; protein ubiquitination.
    • Sequence similaritiesBelongs to the TNF receptor-associated factor family. A subfamily.
      Contains 1 MATH domain.
      Contains 1 RING-type zinc finger.
      Contains 2 TRAF-type zinc fingers.
    • DomainThe coiled coil domain mediates homo- and hetero-oligomerization.
      The MATH/TRAF domain binds to receptor cytoplasmic domains.
    • Post-translational
      modifications
      Sumoylated on Lys-124, Lys-142 and Lys-453 by SUMO1.
      Polyubiquitinated on Lys-124; after cell stimulation with IL-1-beta or TGF-beta. This ligand-induced cell stimulation leads to dimerization/oligomerization of TRAF6 molecules, followed by auto-ubiquitination which involves UBE2N and UBE2V1 and leads to TRAF6 activation. This 'Lys-63' site-specific poly-ubiquitination appears to be associated with the activation of signaling molecules. Endogenous autoubiquitination occurs only for the cytoplasmic form.
    • Cellular localizationCytoplasm. Cytoplasm > cell cortex. Nucleus. Found in the nuclei of some agressive B-cell lymphoma cell lines as well as in the nuclei of both resting and activated T-and B-lymphocytes. Found in punctate nuclear body protein complexes. Ubiquitination may occur in the cytoplasm and sumoylation in the nucleus.
    • Information by UniProt
    • Database links
    • Alternative names
      • E3 ubiquitin-protein ligase TRAF6 antibody
      • Interleukin 1 signal transducer antibody
      • Interleukin-1 signal transducer antibody
      • MGC 3310 antibody
      • MGC:3310 antibody
      • MGC3310 antibody
      • OTTHUMP00000232772 antibody
      • OTTHUMP00000232773 antibody
      • RING finger protein 85 antibody
      • RNF 85 antibody
      • RNF85 antibody
      • TNF receptor associated factor 6 antibody
      • TNF receptor-associated factor 6 antibody
      • TNF receptor-associated factor 6, E3 ubiquitin protein ligase antibody
      • TRAF 6 antibody
      • Traf6 antibody
      • TRAF6_HUMAN antibody
      see all

    Anti-TRAF6 antibody images

    • Western blot against tagged recombinant protein immunogen using ab58369 TRAF6 antibody at 1ug/ml. Predicted band size of immunogen is 38 kDa

    References for Anti-TRAF6 antibody (ab58369)

    ab58369 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab58369.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"